Carboplatin desensitization in the era of target therapies: still worthwhile?-Reference-Cited by-同舟云学术

Carboplatin desensitization in the era of target therapies: still worthwhile?

Published:2024-08-07 Issue: Volume: Page:
ISSN:0256-7040
Container-title:Child's Nervous System
language:en
Short-container-title:Childs Nerv Syst

Author:

Dassi Natália,da Cunha Fernanda Sales,Cappellano Andrea Maria,de Araujo Chayanne Andrade,de Aquino Denise Neiva Santos,de Almeida Daniela Barbosa,da Silva Nasjla Saba,Ensina Luis Felipe Chiaverini

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00381-024-06564-9.pdf

Reference27 articles.

1. Manoharan N, Liu KX, Mueller S, Haas-Kogan DA, Bandopadhayay P (2023) Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era. Neoplasia 36:100857. https://doi.org/10.1016/j.neo.2022.100857

2. Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8(1):30. https://doi.org/10.1186/s40478-020-00902-z

3. de Blank P, Fouladi M, Huse JT (2020) Molecular markers and targeted therapy in pediatric low-grade glioma. J Neurooncol 150(1):5–15. https://doi.org/10.1007/s11060-020-03529-1

4. Manoharan N, Choi J, Chordas C, Zimmerman MA, Scully J, Clymer J, Filbin M, Ullrich NJ, Bandopadhayay P, Chi SN, Yeo KK (2020) Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol 149(2):253–262. https://doi.org/10.1007/s11060-020-03592-8

5. Selt F, van Tilburg CM, Bison B, Sievers P, Harting I, Ecker J, Pajtler KW, Sahm F, Bahr A, Simon M, Jones DTW, Well L, Mautner VF, Capper D, Hernáiz Driever P, Gnekow A, Pfister SM, Witt O, Milde T (2020) Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol 149(3):499–510. https://doi.org/10.1007/s11060-020-03640-3